Antigen News and Research

RSS
Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

Prostate cancer discovery may improve treatment strategies

Prostate cancer discovery may improve treatment strategies

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

First malaria vaccine a step closer

First malaria vaccine a step closer

SutroVax completes $22 million Series A financing

SutroVax completes $22 million Series A financing

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Study findings provide basis for potential development of new methods to control HIV infection

Study findings provide basis for potential development of new methods to control HIV infection

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.